| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Gemini Therapeutics, Inc. /DE | CFO | Common Stock | 17.6K | $1.19M | $67.65 | May 31, 2022 | Direct |
| KalVista Pharmaceuticals, Inc. | Chief Financial Officer | Employee Stock Option (right to buy) | 100K | Sep 9, 2024 | Direct | ||
| Elicio Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy) | 43.2K | Feb 1, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| KALV | KalVista Pharmaceuticals, Inc. | Sep 9, 2024 | 1 | $0 | 4 | Sep 11, 2024 | Chief Financial Officer |
| KALV | KalVista Pharmaceuticals, Inc. | Sep 9, 2024 | 0 | $0 | 3 | Sep 11, 2024 | Chief Financial Officer |
| ELTX | Elicio Therapeutics, Inc. | Feb 1, 2024 | 1 | $0 | 4 | Feb 5, 2024 | Chief Financial Officer |
| ELTX | Elicio Therapeutics, Inc. | Jun 1, 2023 | 1 | $0 | 4 | Jun 5, 2023 | Chief Financial Officer |
| ELTX | Elicio Therapeutics, Inc. | Jun 1, 2023 | 0 | $0 | 3 | Jun 5, 2023 | Chief Financial Officer |
| IRON | Gemini Therapeutics, Inc. /DE | May 31, 2022 | 1 | $10.9K | 4 | Jun 2, 2022 | CFO |
| IRON | Gemini Therapeutics, Inc. /DE | Jan 13, 2022 | 1 | $0 | 4 | Jan 14, 2022 | CFO |
| IRON | Gemini Therapeutics, Inc. /DE | Oct 18, 2021 | 1 | $0 | 4 | Oct 20, 2021 | Chief Financial Officer |
| IRON | Gemini Therapeutics, Inc. /DE | May 14, 2021 | 1 | $72.4K | 4 | May 18, 2021 | Chief Financial Officer |